Disc Medicine (NASDAQ:IRON) Shares Gap Down – Should You Sell?

Disc Medicine, Inc. (NASDAQ:IRON)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $77.08, but opened at $72.47. Disc Medicine shares last traded at $71.8480, with a volume of 222,183 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IRON shares. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a report on Thursday. Truist Financial raised their price objective on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. National Bankshares set a $153.00 target price on Disc Medicine in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, October 8th. Finally, Morgan Stanley restated an “overweight” rating and set a $120.00 price objective on shares of Disc Medicine in a research report on Thursday, January 8th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $119.45.

Disc Medicine Stock Down 0.2%

The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The stock has a market cap of $2.68 billion, a P/E ratio of -13.26 and a beta of 0.87. The company’s 50 day moving average price is $85.55 and its two-hundred day moving average price is $72.42.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.29). As a group, research analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insider Buying and Selling

In other Disc Medicine news, insider Rahul Khara sold 6,500 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the sale, the insider owned 37,793 shares in the company, valued at $2,973,931.17. This represents a 14.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin Bitterman sold 68,923 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $91.24, for a total transaction of $6,288,534.52. Following the completion of the sale, the director owned 14,161 shares in the company, valued at $1,292,049.64. This represents a 82.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 274,470 shares of company stock valued at $24,896,430 over the last ninety days. Company insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP raised its position in Disc Medicine by 257.1% during the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $33,040,000 after acquiring an additional 360,000 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Disc Medicine by 3,329.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock worth $28,416,000 after acquiring an additional 347,403 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Disc Medicine during the 3rd quarter worth about $22,342,000. First Light Asset Management LLC acquired a new position in shares of Disc Medicine during the 3rd quarter worth approximately $15,277,000. Finally, Sio Capital Management LLC raised its position in Disc Medicine by 287.4% during the second quarter. Sio Capital Management LLC now owns 284,787 shares of the company’s stock worth $15,082,000 after acquiring an additional 211,276 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.